An Open Label Phase II Clinical Trial Evaluating the Efficacy and Safety of SHR1459 in Adult Patients With Neuromyelitis Optical Spectrum Disorders (NMOSDs)
Latest Information Update: 28 Mar 2023
At a glance
- Drugs Edralbrutinib (Primary)
- Indications Neuromyelitis optica
- Focus Proof of concept; Therapeutic Use
- Sponsors Reistone Biopharma
- 21 Mar 2023 Status changed from active, no longer recruiting to completed.
- 19 Oct 2021 Status changed from recruiting to active, no longer recruiting.
- 06 Apr 2021 Status changed from not yet recruiting to recruiting.